Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Astrazeneca Plc

22 May 2014 10:42

RNS Number : 8134H
Morgan Stanley & Co. LLC
22 May 2014
 



 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley & Co. LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

21 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 USD 0.25 ORDINARY

 PURCHASES

 27,573

 44.4252 GBP

 43.8458 GBP

 USD 0.25 ORDINARY

 SALES

 27,573

 44.2000 GBP

 43.8457 GBP

 ADRS

 PURCHASES

 1,101,966.00 (Traded in ADR form)

 75.2300 USD

 72.9800 USD

 ADRS

 SALES

 1,066,845.00 (Traded in ADR form)

 75.2300 USD

 72.9100 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

ADRS

 PUT

PURCHASE

 2,000.00 (Traded in ADR form)

 65.0000

 A

 21/06/2014

 0.3000 USD

ADRS

 PUT

PURCHASE

 100.00 (Traded in ADR form)

 65.0000

 A

 21/06/2014

 0.3400 USD

ADRS

 PUT

PURCHASE

 200.00 (Traded in ADR form)

 65.0000

 A

 21/06/2014

 0.3400 USD

ADRS

 CALL

PURCHASE

 300.00 (Traded in ADR form)

 90.0000

 A

 21/06/2014

 0.3400 USD

ADRS

 PUT

PURCHASE

 200.00 (Traded in ADR form)

 65.0000

 A

 21/06/2014

 0.3500 USD

ADRS

 CALL

PURCHASE

 2,000.00 (Traded in ADR form)

 87.5000

 A

 21/06/2014

 0.5000 USD

ADRS

 PUT

PURCHASE

 200.00 (Traded in ADR form)

 67.5000

 A

 21/06/2014

 0.7200 USD

ADRS

 PUT

PURCHASE

 300.00 (Traded in ADR form)

 67.5000

 A

 21/06/2014

 0.7200 USD

ADRS

 PUT

PURCHASE

 100.00 (Traded in ADR form)

 67.5000

 A

 21/06/2014

 0.7200 USD

ADRS

 PUT

PURCHASE

 200.00 (Traded in ADR form)

 67.5000

 A

 21/06/2014

 0.7200 USD

ADRS

 CALL

PURCHASE

 300.00 (Traded in ADR form)

 85.0000

 A

 21/06/2014

 0.9200 USD

ADRS

 CALL

PURCHASE

 100.00 (Traded in ADR form)

 85.0000

 A

 21/06/2014

 1.1000 USD

ADRS

 CALL

PURCHASE

 200.00 (Traded in ADR form)

 80.0000

 A

 21/06/2014

 1.2000 USD

ADRS

 CALL

PURCHASE

 200.00 (Traded in ADR form)

 80.0000

 A

 21/06/2014

 1.2500 USD

ADRS

 PUT

PURCHASE

 100.00 (Traded in ADR form)

 62.5000

 A

 18/10/2014

 1.2700 USD

ADRS

 PUT

PURCHASE

 200.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 1.3300 USD

ADRS

 CALL

PURCHASE

 1,200.00 (Traded in ADR form)

 82.5000

 A

 21/06/2014

 1.3900 USD

ADRS

 PUT

PURCHASE

 1,000.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 1.4600 USD

ADRS

 CALL

PURCHASE

 100.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 600.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 500.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 500.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 700.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 100.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 1,000.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 100.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 1,000.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 300.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 400.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 100.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.6500 USD

ADRS

 CALL

PURCHASE

 1,000.00 (Traded in ADR form)

 80.0000

 A

 21/06/2014

 1.6600 USD

ADRS

 CALL

PURCHASE

 2,000.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.7000 USD

ADRS

 PUT

PURCHASE

 500.00 (Traded in ADR form)

 70.0000

 A

 19/07/2014

 2.0000 USD

ADRS

 CALL

PURCHASE

 111,000.00 (Traded in ADR form)

 80.0000

 A

 21/06/2014

 2.0400 USD

ADRS

 CALL

PURCHASE

 74,000.00 (Traded in ADR form)

 80.0000

 A

 21/06/2014

 2.0400 USD

ADRS

 CALL

PURCHASE

 500.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 2.2500 USD

ADRS

 PUT

PURCHASE

 2,400.00 (Traded in ADR form)

 72.5000

 A

 21/06/2014

 2.3500 USD

ADRS

 PUT

PURCHASE

 100.00 (Traded in ADR form)

 72.5000

 A

 21/06/2014

 2.5300 USD

ADRS

 CALL

PURCHASE

 1,600.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 2.5500 USD

ADRS

 CALL

PURCHASE

 400.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 2.5500 USD

ADRS

 CALL

PURCHASE

 200.00 (Traded in ADR form)

 85.0000

 A

 17/01/2015

 2.5600 USD

ADRS

 CALL

PURCHASE

 10,000.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 2.6000 USD

ADRS

 CALL

PURCHASE

 1,100.00 (Traded in ADR form)

 77.5000

 A

 19/07/2014

 2.7000 USD

ADRS

 CALL

PURCHASE

 1,100.00 (Traded in ADR form)

 77.5000

 A

 19/07/2014

 2.7000 USD

ADRS

 CALL

PURCHASE

 1,100.00 (Traded in ADR form)

 77.5000

 A

 19/07/2014

 2.7000 USD

ADRS

 CALL

PURCHASE

 800.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 2.8000 USD

ADRS

 CALL

PURCHASE

 100.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 2.8300 USD

ADRS

 CALL

PURCHASE

 100.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 3.0000 USD

ADRS

 CALL

PURCHASE

 200.00 (Traded in ADR form)

 80.0000

 A

 18/10/2014

 3.2500 USD

ADRS

 CALL

PURCHASE

 200.00 (Traded in ADR form)

 75.0000

 A

 19/07/2014

 3.7100 USD

ADRS

 PUT

PURCHASE

 700.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 3.8500 USD

ADRS

 CALL

PURCHASE

 1,100.00 (Traded in ADR form)

 72.5000

 A

 19/07/2014

 4.7000 USD

ADRS

 CALL

PURCHASE

 1,100.00 (Traded in ADR form)

 72.5000

 A

 19/07/2014

 4.7000 USD

ADRS

 PUT

PURCHASE

 300.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 5.5000 USD

ADRS

 CALL

PURCHASE

 300.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 5.5000 USD

ADRS

 PUT

PURCHASE

 200.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 5.6800 USD

ADRS

 CALL

PURCHASE

 500.00 (Traded in ADR form)

 70.0000

 A

 19/07/2014

 6.1000 USD

ADRS

 CALL

SALE

 1,000.00 (Traded in ADR form)

 87.5000

 A

 21/06/2014

 0.2500 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 87.5000

 A

 21/06/2014

 0.2500 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 87.5000

 A

 21/06/2014

 0.2500 USD

ADRS

 CALL

SALE

 1,000.00 (Traded in ADR form)

 87.5000

 A

 21/06/2014

 0.2500 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 87.5000

 A

 21/06/2014

 0.2500 USD

ADRS

 CALL

SALE

 1,800.00 (Traded in ADR form)

 87.5000

 A

 21/06/2014

 0.2500 USD

ADRS

 CALL

SALE

 5,000.00 (Traded in ADR form)

 87.5000

 A

 21/06/2014

 0.2500 USD

ADRS

 PUT

SALE

 500.00 (Traded in ADR form)

 65.0000

 A

 21/06/2014

 0.3000 USD

ADRS

 CALL

SALE

 25,000.00 (Traded in ADR form)

 85.0000

 A

 21/06/2014

 0.4000 USD

ADRS

 CALL

SALE

 5,000.00 (Traded in ADR form)

 90.0000

 A

 19/07/2014

 0.4000 USD

ADRS

 PUT

SALE

 1,100.00 (Traded in ADR form)

 65.0000

 A

 19/07/2014

 0.6500 USD

ADRS

 PUT

SALE

 2,000.00 (Traded in ADR form)

 67.5000

 A

 21/06/2014

 0.6600 USD

ADRS

 PUT

SALE

 1,000.00 (Traded in ADR form)

 67.5000

 A

 21/06/2014

 0.7500 USD

ADRS

 PUT

SALE

 100.00 (Traded in ADR form)

 67.5000

 A

 21/06/2014

 0.7500 USD

ADRS

 PUT

SALE

 200.00 (Traded in ADR form)

 65.0000

 A

 19/07/2014

 0.7500 USD

ADRS

 CALL

SALE

 300.00 (Traded in ADR form)

 85.0000

 A

 21/06/2014

 0.8200 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 82.5000

 A

 21/06/2014

 0.8600 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 82.5000

 A

 21/06/2014

 0.9000 USD

ADRS

 CALL

SALE

 800.00 (Traded in ADR form)

 85.0000

 A

 19/07/2014

 1.1000 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 82.5000

 A

 21/06/2014

 1.2000 USD

ADRS

 PUT

SALE

 200.00 (Traded in ADR form)

 67.5000

 A

 19/07/2014

 1.2500 USD

ADRS

 CALL

SALE

 200.00 (Traded in ADR form)

 82.5000

 A

 21/06/2014

 1.3000 USD

ADRS

 CALL

SALE

 5,000.00 (Traded in ADR form)

 82.5000

 A

 21/06/2014

 1.3000 USD

ADRS

 CALL

SALE

 200.00 (Traded in ADR form)

 82.5000

 A

 21/06/2014

 1.4000 USD

ADRS

 PUT

SALE

 1,000.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 1.4000 USD

ADRS

 PUT

SALE

 200.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 1.4300 USD

ADRS

 PUT

SALE

 1,000.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 1.4500 USD

ADRS

 PUT

SALE

 100.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 1.4600 USD

ADRS

 PUT

SALE

 200.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 1.5000 USD

ADRS

 CALL

SALE

 300.00 (Traded in ADR form)

 82.5000

 A

 19/07/2014

 1.5500 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 1.7500 USD

ADRS

 PUT

SALE

 100.00 (Traded in ADR form)

 65.0000

 A

 18/10/2014

 1.9700 USD

ADRS

 CALL

SALE

 300.00 (Traded in ADR form)

 80.0000

 A

 21/06/2014

 2.0200 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 80.0000

 A

 19/07/2014

 2.2500 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 80.0000

 A

 19/07/2014

 2.3000 USD

ADRS

 PUT

SALE

 1,000.00 (Traded in ADR form)

 72.5000

 A

 21/06/2014

 2.3500 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 2.3500 USD

ADRS

 PUT

SALE

 100.00 (Traded in ADR form)

 72.5000

 A

 21/06/2014

 2.4500 USD

ADRS

 PUT

SALE

 1,000.00 (Traded in ADR form)

 72.5000

 A

 21/06/2014

 2.5000 USD

ADRS

 PUT

SALE

 700.00 (Traded in ADR form)

 72.5000

 A

 21/06/2014

 2.5500 USD

ADRS

 CALL

SALE

 1,200.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 2.6000 USD

ADRS

 CALL

SALE

 1,200.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 2.7900 USD

ADRS

 CALL

SALE

 200.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 2.8000 USD

ADRS

 CALL

SALE

 200.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 2.8500 USD

ADRS

 CALL

SALE

 500.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 2.9000 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 3.2200 USD

ADRS

 CALL

SALE

 300.00 (Traded in ADR form)

 80.0000

 A

 18/10/2014

 3.3900 USD

ADRS

 CALL

SALE

 200.00 (Traded in ADR form)

 80.0000

 A

 18/10/2014

 3.3900 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 80.0000

 A

 18/10/2014

 3.4500 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 3.7000 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 75.0000

 A

 19/07/2014

 3.7400 USD

ADRS

 CALL

SALE

 100.00 (Traded in ADR form)

 75.0000

 A

 21/06/2014

 3.7800 USD

ADRS

 CALL

SALE

 74,000.00 (Traded in ADR form)

 80.0000

 A

 17/01/2015

 4.5400 USD

ADRS

 CALL

SALE

 111,000.00 (Traded in ADR form)

 80.0000

 A

 17/01/2015

 4.5400 USD

ADRS

 CALL

SALE

 200.00 (Traded in ADR form)

 72.5000

 A

 21/06/2014

 4.7100 USD

ADRS

 CALL

SALE

 1,900.00 (Traded in ADR form)

 72.5000

 A

 21/06/2014

 4.7400 USD

ADRS

 PUT

SALE

 100.00 (Traded in ADR form)

 77.5000

 A

 21/06/2014

 5.3000 USD

ADRS

 CALL

SALE

 200.00 (Traded in ADR form)

 70.0000

 A

 21/06/2014

 5.6000 USD

ADRS

 CALL

SALE

 400.00 (Traded in ADR form)

 70.0000

 A

 18/10/2014

 7.7100 USD

ADRS

 CALL

SALE

 200.00 (Traded in ADR form)

 70.0000

 A

 17/01/2015

 8.1700 USD

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

22 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERSESSUEFLSELI
Date   Source Headline
21st Feb 202311:00 amRNSAnnual Financial Report
13th Feb 20232:01 pmRNSDirector/PDMR Shareholding
13th Feb 20232:00 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSFinal Results
1st Feb 20233:00 pmRNSTotal Voting Rights
26th Jan 20236:15 pmRNSUpdate on Evusheld US EUA
16th Jan 20237:00 amRNSAcquisition of Neogene Therapeutics completed
11th Jan 20231:00 pmRNSAirsupra (PT027) approved in US for asthma
9th Jan 20237:00 amRNSAstraZeneca acquire CinCor for cardiorenal asset
3rd Jan 20233:00 pmRNSTotal Voting Rights
30th Dec 202211:00 amRNSDirector/PDMR Shareholding
28th Dec 20227:05 amRNSCalquence Japan approval for treatment-naïve CLL
28th Dec 20227:00 amRNSImfinzi, Imjudo approved in Japan for 3 cancers
21st Dec 20227:05 amRNSLynparza approved in EU for prostate cancer
21st Dec 20227:00 amRNSImfinzi approved in EU for biliary tract cancer
19th Dec 20227:20 amRNSEnhertu recommended for EU approval in HER2-low BC
19th Dec 20227:15 amRNSEnhertu approved in EU for gastric cancer
19th Dec 20227:10 amRNSImfinzi + Imjudo recommended for approvals in EU
19th Dec 20227:05 amRNSUpdate on Imfinzi PEARL trial
19th Dec 20227:00 amRNSForxiga CHMP opinion for symptomatic chronic HF
15th Dec 20227:00 amRNSUpdate on US review of Lynparza PROpel sNDA
8th Dec 20221:30 pmRNSCapivasertib PFS in HR-positive breast cancer
1st Dec 20223:00 pmRNSBlock listing Interim Review
1st Dec 20223:00 pmRNSTotal Voting Rights
30th Nov 20227:05 amRNSAstraZeneca announces sale of West Chester site
29th Nov 20227:00 amRNSAstraZeneca to acquire Neogene Therapeutics
23rd Nov 20223:30 pmRNSDirector/PDMR Shareholding
14th Nov 20227:10 amRNSEnhertu recommended for EU approval in gastric
14th Nov 20227:05 amRNSImfinzi recommended for approval in the EU for BTC
14th Nov 20227:00 amRNSLynparza combo recommended in the EU for mCRPC
11th Nov 20227:00 amRNSImfinzi + Imjudo approved in US for lung cancer
10th Nov 20227:00 amRNSYTD and Q3 2022 Results
9th Nov 20227:00 amRNSFDA Advisory Committee recommends PT027 in asthma
4th Nov 20227:00 amRNSBeyfortus (nirsevimab) approved in EU
1st Nov 20223:00 pmRNSTotal Voting Rights
26th Oct 20227:00 amRNSCapivasertib Phase III trial met primary endpoints
25th Oct 20227:00 amRNSUpdate on MESSINA Phase III trial
24th Oct 20227:00 amRNSImfinzi + Imjudo approved in advanced liver cancer
3rd Oct 20223:00 pmRNSTotal Voting Rights
30th Sep 202210:30 amRNSBoard Committee Changes
27th Sep 20227:05 amRNSKoselugo approved in Japan for NF1
27th Sep 20227:00 amRNSTezspire approved in Japan for severe asthma
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
22nd Sep 20227:00 amRNSLynparza approved in China for ovarian cancer
21st Sep 20227:00 amRNSTezspire approved in the EU for severe asthma
20th Sep 20227:00 amRNSEvusheld approved in EU for COVID-19 treatment
16th Sep 20227:10 amRNSDanicopan Phase III trial met primary endpoint
16th Sep 20227:05 amRNSEvusheld positive CHMP opinion in EU
16th Sep 20227:00 amRNSNirsevimab recommended for approval in EU by CHMP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.